Skip to main content
. 2022 Dec 28;15(1):187. doi: 10.3390/cancers15010187

Figure A2.

Figure A2

(A,C) Progression-free survival (PFS) and (B,D) overall survival (OS) of patients receiving different epidermal growth factor receptor tyrosine kinase inhibitors and (A,B) undergoing or (C,D) not undergoing surgery (OP) or radiotherapy (RT) for a brain tumor.